TABLE 6.
Log10 CFU of M. avium/lung in BALB/c and nude mice with and without multidrug treatment from week 4 to week 16 postinfection
| Mouse strain and treatmentc | Mean log10 CFU/lung (SD) by time point postinfection |
||||
|---|---|---|---|---|---|
| Day 1 | Wk 2 | Wk 4 | Wk 8a | Wk 16b | |
| BALB/c | |||||
| Untreated | 5.14 (0.25) | 5.86 (0.18) | 6.39 (0.16) | 6.90 (0.24) | 7.08 (0.26) |
| CLR-EMB-RIF | 5.50 (0.07) | 4.87 (0.07) | |||
| MXF-EMB-RIF | 5.56 (0.09) | 5.79 (0.16) | |||
| CLR-MXF-EMB-RIF | 5.53 (0.13) | 4.68 (0.57) | |||
| Nude | |||||
| Untreated | 5.26 (0.04) | 6.25 (0.03) | 6.79 (0.57) | 8.94 (0.51) | 8.84 (0.34) |
| CLR-EMB-RIF | 5.92 (0.42) | 6.00 (0.18) | |||
| MXF-EMB-RIF | 6.62 (0.49) | 7.65 (0.60) | |||
| CLR-MXF-EMB-RIF | 6.34 (0.20) | 5.86 (0.16) | |||
At week 8 (after 1 month of treatment) in both BALB/c and nude mice, the lung CFU counts in all treated groups were statistically significantly different from those in the untreated mice (P ≤ 0.0001 for each group).
At week 16 (after 2 months of treatment) in both BALB/c and nude mice, the lung CFU counts in all treated groups were statistically significantly different from those in the untreated mice (P ≤ 0.0001 for each group); the lung CFU counts were also statistically significant between either the CLR-EMB-RIF or CLR-MXF-EMB-RIF group and the MXF-EMB-RIF group (P ≤ 0.0001).
CLR, clarithromycin; EMB, ethambutol; RIF, rifampin; MXF, moxifloxacin.